Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (660 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
Methods and techniques used to genetically modify cells' biosynthetic product output and develop conditions for growing the cells as bioreactors.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Engineering, Metabolic.
Where it fits in the MeSH classification
- Broader topics
- Genetic Engineering; Cell Engineering
- See also
- Metabolic Flux Analysis
Related concepts
- Bioreactors
Research landscape
PubMed indexes 11,659 records tagged with the MeSH heading “Metabolic Engineering” (counts retrieved 2026-10-29). 6,008 of them (51.5%) were published from 2020 onward, and the busiest period so far is 2020 onward with 6,008 records.
Reviews account for 3,143 records (27.0%) and meta-analyses for 2. Randomized controlled trials number 0 (0.0%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.
Show the data
| Period | Records |
|---|---|
| through 1999 | 0 |
| 2000-2009 | 2 |
| 2010-2019 | 5,791 |
| 2020 onward | 6,008 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 3,143 | 27.0% |
| Meta-analyses | 2 | 0.0% |
| Randomized controlled trials | 0 | 0.0% |
Method: PubMed query "Metabolic Engineering"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.
Reading the evidence in genetics and genomics
Genetic findings vary widely in strength. A variant linked to a condition in one study may not replicate in other ancestries, and most common variants have small effects that are meaningful only in aggregate. Studies of rare, high-impact variants can support strong causal claims about a gene, while association studies describe statistical links that need functional and independent replication. Check the sample size, the ancestry of participants, whether results were replicated, and whether a laboratory or clinical outcome was actually measured.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
Engineering controllable alteration of malonyl-CoA levels to enhance polyketide production [1]
Abstract reading summary — source excerpts
- Opening excerpt
- Heterologous expression of polyketide synthase (PKS) genes in Escherichia coli has enabled the production of various valuable natural and synthetic products.
- Closing excerpt
- coli as a host for polyketide biosynthesis and advances understanding of M-CoA metabolism in microbial systems.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (135 words)
Heterologous expression of polyketide synthase (PKS) genes in Escherichia coli has enabled the production of various valuable natural and synthetic products. However, the limited availability of malonyl-CoA (M-CoA) in E. coli remains a substantial impediment to high-titer polyketide production. Here we address this limitation by disrupting the native M-CoA biosynthetic pathway and introducing an orthogonal pathway comprising a malonate transporter and M-CoA ligase, enabling efficient M-CoA biosynthesis under malonate supplementation. This approach substantially increases M-CoA levels, enhancing fatty acid and polyketide titers while reducing the promiscuous activity of PKSs toward undesired acyl-CoA substrates. Subsequent adaptive laboratory evolution of these strains provides insights into M-CoA regulation and identifies mutations that further boost M-CoA and polyketide production. This strategy improves E. coli as a host for polyketide biosynthesis and advances understanding of M-CoA metabolism in microbial systems.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 40500421 · DOI · PMC12303837
Balancing Cell Growth and Product Synthesis for Efficient Microbial Cell Factories [2]
Abstract reading summary — source excerpts
- Opening excerpt
- The sustainable, bio-based production of industrially valuable chemicals and materials from renewable, non-edible biomass through biorefineries has emerged as a vital strategy for tackling urgent global challenges, including climate change, and for realizing the "net zero carbon" commitments recently pledged by nations worldwide.
- Closing excerpt
- It also explores the remaining challenges and future directions for reprogramming microbial metabolism to harmonize growth with high-level production.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (141 words)
The sustainable, bio-based production of industrially valuable chemicals and materials from renewable, non-edible biomass through biorefineries has emerged as a vital strategy for tackling urgent global challenges, including climate change, and for realizing the "net zero carbon" commitments recently pledged by nations worldwide. Metabolic engineering has played a central role in enabling the development of microbial strains capable of efficiently overproducing a diverse array of target compounds. Nevertheless, engineered microbial cell factories often face inherent trade-offs between product synthesis and cell growth, frequently resulting in diminished fitness or loss-of-function phenotypes. This review highlights recent advances in metabolic engineering strategies aims at reconciling this conflict, encompassing pathway optimization, dynamic regulation, orthogonal system design, microbial consortia engineering, fermentation process control, and integrative metabolic modeling. It also explores the remaining challenges and future directions for reprogramming microbial metabolism to harmonize growth with high-level production.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 40966432 · DOI · PMC12561436
Therapeutic engineering of the gut microbiome using synthetic biology and metabolic tools: a comprehensive review with E. coli Nissle 1917 as a model case study [3]
Abstract reading summary — source excerpts
- Opening excerpt
- The human gut microbiome significantly influences host physiology, metabolism, and immune function.
- Closing excerpt
- This combination of developments demonstrates the potential of synthetic microbiome engineering to provide precision biotherapeutics for various gut-related conditions.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (243 words)
The human gut microbiome significantly influences host physiology, metabolism, and immune function. The engineering of microbial communities represents a significant advancement in contemporary biotechnology. Conventional methods, including Fecal Microbiota Transplantation (FMT) and probiotic administration, exhibit limitations in efficacy and raise safety and reproducibility concerns; however, they have shown potential therapeutic benefits. Recent progress in biocatalysis and metabolic engineering has led to the development of genetically tractable gut bacteria for targeted therapeutic purposes, particularly in the last five years. This chapter offers an overview of the development of microbiota-based interventions, from early recombinant probiotics to advanced synthetic biology platforms that can detect and respond to host and environmental signals. This analysis examines the mechanistic aspects of enzyme engineering, including improvements in metabolic pathways for the production of short-chain fatty acids, the breakdown of harmful metabolites, and the biosynthesis of immunomodulatory compounds. This review also examines conditions including inflammatory bowel disease, metabolic dysfunction, and colorectal cancer, highlighting microbial production systems pertinent to gut health. The engineering of Escherichia coli Nissle 1917 to produce phenylalanine ammonia-lyase (PAL) and L-amino acid deaminase (LAAD) represents a significant advancement in gut-based metabolic intervention for patients with phenylketonuria (PKU) by degrading excess phenylalanine. Recent studies offer peer-reviewed evidence supporting the translational potential of these inventions, as demonstrated through figures and tables highlighting engineered metabolic circuits, therapeutic outputs, and strain performance metrics. This combination of developments demonstrates the potential of synthetic microbiome engineering to provide precision biotherapeutics for various gut-related conditions.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 40767874 · DOI · PMC12328466
Synthetic Biology and Metabolic Engineering of Microalgae for Sustainable Lipid and Terpenoid Production: An Updated Perspective [4]
Abstract reading summary — source excerpts
- Opening excerpt
- Microalgae are increasingly recognised as powerful platforms for the sustainable production of lipids and terpenoids, with expanding applications in the food, fuel and biomanufacturing industries.
- Closing excerpt
- By capturing these up-to-date insights, this review outlines the current trajectory of microalgal biotechnology toward scalable, carbon-neutral biofactories for polyunsaturated fatty acids (PUFAs) and diverse terpenoids, reinforcing their role in global sustainability and the circular bioeconomy.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (141 words)
Microalgae are increasingly recognised as powerful platforms for the sustainable production of lipids and terpenoids, with expanding applications in the food, fuel and biomanufacturing industries. In this updated review, we consolidate and critically assess the most recent advances in synthetic biology and metabolic engineering of key microalgal models, including Chlamydomonas reinhardtii, Nannochloropsis spp. and Phaeodactylum tricornutum. We focus on developments that have emerged in the latest waves of research, emphasising novel genetic toolkits that accelerate the Design-Build-Test-Learn (DBTL) cycle, breakthroughs in genome-scale metabolic modelling, and innovative strategies for organelle-targeted biosynthesis of high-value compounds. Recent case studies are compared to highlight trends in successful engineering approaches. By capturing these up-to-date insights, this review outlines the current trajectory of microalgal biotechnology toward scalable, carbon-neutral biofactories for polyunsaturated fatty acids (PUFAs) and diverse terpenoids, reinforcing their role in global sustainability and the circular bioeconomy.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41117552 · DOI · PMC12946468
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article Relieving metabolic burden to improve robustness and bioproduction by industrial microorganisms [5]
- Research article Structural diversity, evolutionary origin, and metabolic engineering of plant specialized benzylisoquinoline alkaloids [6]
- Research article Ogataea polymorpha as a next-generation chassis for industrial biotechnology [7]
- Research article Melanin in fungi: advances in structure, biosynthesis, regulation, and metabolic engineering [8]
- Research article Advances in Flavonoid and Derivative Biosynthesis: Systematic Strategies for the Construction of Yeast Cell Factories [9]
- Research article Flavonoid-Lignin Crosstalk: Engineering Metabolic Flux for Optimised Plant Growth and Stress Resilience [10]
References
- Klass SH, Wesselkamper M, Cowan AE, Lee N, Lanclos N, Cheong S, et al.. Engineering controllable alteration of malonyl-CoA levels to enhance polyketide production. . 2025. PMID 40500421 · DOI · PMC12303837
- Liu L, Ding D, Wang H, Ren X, Lee SY, Zhang D. Balancing Cell Growth and Product Synthesis for Efficient Microbial Cell Factories. . 2025. PMID 40966432 · DOI · PMC12561436
- Sadhu S, Paul T, Yadav N. Therapeutic engineering of the gut microbiome using synthetic biology and metabolic tools: a comprehensive review with E. coli Nissle 1917 as a model case study. . 2025. PMID 40767874 · DOI · PMC12328466
- Shitanaka T, Wang Y, Do S, Yuson J, Khanal SK, Zienkiewicz K, et al.. Synthetic Biology and Metabolic Engineering of Microalgae for Sustainable Lipid and Terpenoid Production: An Updated Perspective. . 2026. PMID 41117552 · DOI · PMC12946468
- Mao J, Zhang H, Chen Y, Wei L, Liu J, Nielsen J, et al.. Relieving metabolic burden to improve robustness and bioproduction by industrial microorganisms. Biotechnol Adv. 2024. PMID 38944217 · DOI
- Tian Y, Kong L, Li Q, Wang Y, Wang Y, An Z, et al.. Structural diversity, evolutionary origin, and metabolic engineering of plant specialized benzylisoquinoline alkaloids. Nat Prod Rep. 2024. PMID 39360417 · DOI
- Xie L, Yu W, Gao J, Wang H, Zhou YJ. Ogataea polymorpha as a next-generation chassis for industrial biotechnology. Trends Biotechnol. 2024. PMID 38622041 · DOI
- Qin Y, Xia Y. Melanin in fungi: advances in structure, biosynthesis, regulation, and metabolic engineering. Microb Cell Fact. 2024. PMID 39696244 · DOI · PMC11657710
- Wang J, Chen C, Guo Q, Gu Y, Shi TQ. Advances in Flavonoid and Derivative Biosynthesis: Systematic Strategies for the Construction of Yeast Cell Factories. ACS Synth Biol. 2024. PMID 39145487 · DOI
- Yang J, Zhang Y, Jia J, Wang C, Fu Y. Flavonoid-Lignin Crosstalk: Engineering Metabolic Flux for Optimised Plant Growth and Stress Resilience. Plant Cell Environ. 2025. PMID 40793933 · DOI
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-29.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.